Association Of Smokeless Tobacco Research Articles

Association of Smokeless Tobacco and Complications Following Ankle and Hindfoot Arthrodesis.

The purpose of this study was to (1) evaluate the rates of postoperative complications following ankle or hindfoot arthrodesis among current smokeless tobacco users and people who smoke compared to matched controls, and (2) compare rates of postoperative complications in current smokeless tobacco users vs people who smoke tobacco cigarettes. A retrospective cohort study was conducted using a large national database. For patients who underwent ankle or hindfoot arthrodesis, smokeless tobacco users (n = 131) and people who smoke (n = 1948) were matched 1:4 with controls, and smokeless tobacco users (n = 131) were matched 1:4 with people who smoke tobacco cigarettes (n = 524). Orthopaedic complications within 90 days, 1 year, and 2 years were compared using multivariable logistic regressions. Within 90 days of ankle or hindfoot arthrodesis, smokeless tobacco users demonstrated significantly higher rates of hardware removal (odds ratio [OR] 5.01, 95% CI 1.65-15.20), wound disruption or dehiscence (OR 3.00, 95% CI 1.21-7.44), and pooled complications (16.0% vs 5.9%, OR 2.84, 95% CI 1.50-5.38) compared with tobacco-naïve controls. The rates of hardware removal, wound disruption and dehiscence, and pooled complications remained significant in the smokeless tobacco cohort at 1 and 2 years. At 2 years following ankle or hindfoot arthrodesis, smokeless tobacco users additionally demonstrated significantly higher rates of infection (OR 6.08, 95% CI 1.15-32.05) and nonunion (OR 2.35, 95% CI 1.31-4.20) compared with tobacco-naïve controls. Within 90 days of ankle or hindfoot arthrodesis, smokeless tobacco users demonstrated significantly lower rates of malunion or nonunion than patients who smoke tobacco cigarettes (OR 0.34, 95% CI 0.12-0.97), whereas all other complications were not significantly different. Smokeless tobacco use is associated with higher rates of complications following ankle or hindfoot arthrodesis compared with tobacco-naïve controls, and physicians should screen for smokeless tobacco use specifically and encourage cessation before operating electively. Level III, retrospective cohort study.

Evidence of Association of CYP1A1 Expression in Blood Lymphocytes and Clinicopathological Variables in Oral Cancer.

Association of smokeless tobacco (SLT) with oral cancer is well documented. The nitrosamines of SLT are metabolically bioactivated by CYP1A1. Therefore, in this pilot study, we investigated association of CYP1A1 expression with polymorphism, clinicopathological variables and outcome in exclusive SLT chewers. Semiquantitative RT-PCR analysis on RNA isolated from peripheral blood lymphocytes of 65 histopathologically confirmed cases revealed increased CYP1A1 mRNA expression in Msp I (CYP1A1*2A) and Ile/Val (CYP1A1*2C) polymorphic variants. A higher trend of CYP1A1 mRNA levels in invasive and recurrent tumors which also associated with shorter disease free and overall survival was seen. Odds ratio analysis indicated the association of higher CYP1A1 mRNA levels with disease aggressiveness i.e. metastasis and invasion. Study revealed wider oncogenic role of CYP1A1 in oral cancer patients and justifies further studies and analysis in a large cohort.

Corrigendum to: Association of smokeless tobacco and cerebrovascular accident: a systematic review and meta-analysis of global data.

Corrigendum to: Association of smokeless tobacco and cerebrovascular accident: a systematic review and meta-analysis of global data.

Association of Smokeless Tobacco with Coronary Heart Diseases

Introduction: Coronary heart diseases (CHDs) are one of the leading killers in our country. Both smoking and smokeless tobacco (SLT) are major risk factors for CHDs. Bangladesh is one of the top-ranked countries in the world regarding SLT users.
 Objectives: To determine the relation between smokeless tobacco uses and CHDs.
 Materials and Methods: This case-control observational study was conducted at the outpatientdepartment of Combined Military Hospital, Dhaka and National Institute of Cardiovascular Diseases and Hospital from July 2017 to June 2018 among selected 62 adultcoronary heart diseasepatients (Cases) and 62 age and sex-matched non-CHDs patients (Controls).
 Results: In Cases; 61.3% of respondents were male and mean age was 51.56 + 11.46 years. In Controls; 56.5 % respondents were male and mean age was 48.15 ± 12.53 years. Among the CHDs cases 19 (30.6%) was SLT users but in non-CHD cases it was only 10(16.1%) and this difference was not statistically significant. All the SLT users in CHDs Controlswere longduration users and majority uses Gul or Jorda.
 Conclusion: Number of SLT users was more in CHDs Cases than non-CHD Controls but this difference was not statistically significant. Further studies with more sample size are recommended to find the relation between SLT users and CHDS.
 Journal of Armed Forces Medical College Bangladesh Vol.14 (2) 2018: 106-108

Risk of Coronary Heart Disease Among Smokeless Tobacco Users: Results of Systematic Review and Meta-Analysis of Global Data.

Use of smokeless tobacco (SLT) products has been linked to multiple adverse effects, especially precancer and cancer of oral cavity. However, the association of SLT use with risk of coronary heart disease (CHD) is shrouded with controversy due to conflicting results in the literature. The present meta-analysis aimed to evaluate the risk of CHD among adult ever-users of SLT products along with sub-group analysis. The analysis included studies retrieved from a systematic literature search for published articles assessing risk of CHD with SLT use. Two authors independently extracted risk estimates and study characteristics of the included studies. Summary relative risks were estimated using the random-effect model. Twenty studies from four WHO regions were included in the analysis. The summary risk of CHD in SLT users was not significantly positive (1.05, 95% CI = 0.96 to 1.15) although a higher risk of fatal CHD was seen (1.10, 95% CI = 1.00 to 1.20). The risk was significant for users in European Region (1.30, 95% CI = 1.14 to 1.47). The results remained unchanged even after strict adjustment for smoking. Product-wise analysis revealed a significant positive association of fatal CHD with snus/snuff use (1.37, 95% CI = 1.14 to 1.61). The SLT-attributable fraction of fatal CHD was calculated to be 0.3%, highest being for European region (5%). A significant positive association was detected between SLT use and risk of fatal CHD, especially for European users and those consuming snus/snuff. In view of the positive association even after strict adjustment for smoking, these results underscore the need for inclusion of cessation efforts for smokeless tobacco in addition to smoking for control of fatal cardiovascular diseases. The present meta-analysis demonstrates a global perspective of association between coronary heart disease (CHD) and use of smokeless tobacco (SLT), especially for fatal cardiac events, even with strict adjustment for smoking. There appears to be some difference in this effect based on the type of SLT product used. These results highlight the independent deleterious effect of SLT products on the outcome of CHD and might help to resolve the long-standing controversy regarding the association of SLT with the risk of CHD. Hence, we propose that in addition to smoking, cessation efforts should be directed towards SLT products as well, for control of cardiovascular diseases.

A systematic review on association between smokeless tobacco & cardiovascular diseases.

Background & objectives:The association of smokeless tobacco (SLT) with cardiovascular diseases has remained controversial due to conflicting reports from various countries. Earlier meta-analyses have shown significantly higher risk of fatal myocardial infarction and stroke in SLT users. However, the risk of hypertension (HTN) with SLT products has not been reviewed earlier. This systematic review was undertaken to summarize the evidence available from global literature on the association of SLT with cardiovascular outcomes – heart disease, stroke and HTN.Methods:A systematic literature search was performed in PubMed and Google Scholar since their inception till October 2017 using pre-decided search terms and inclusion/exclusion criteria. Data were extracted from studies included independently by two authors and reviewed.Results:The review included 50 studies - 23 on heart disease, 14 on stroke and 14 on HTN. Majority of the studies evaluating heart disease or stroke were conducted in the European Region and most of these did not find a significant association between SLT use and either of these outcomes. On the other hand, 70 per cent of the studies on HTN were reported from South-East Asian Region and about half of the studies found a higher risk of HTN in SLT users.Interpretation & conclusions:Current available evidence is insufficient to conclusively support the association of cardiovascular diseases with SLT use due to variability in results and methodological constraints in most of the studies. Region and product-specific well-designed studies are required to provide this evidence to the policymakers. However, advice on cessation of SLT products should be offered to patients presenting with cardiovascular diseases.

Substitution of smokeless tobacco for cigarettes in Buerger's disease does not prevent limb loss

Buerger's Disease, characterized by segmental, inflammatory, occlusive disease of the distal small and medium sized arteries, predominantly affects young men who are cigarette smokers. The disease may lead to ischemia, necrosis, and amputation of distal extremities; most patients have significant improvement in symptoms if smoking is discontinued. We report a patient who experienced progression of biopsy-proven Buerger's disease, after substituting smokeless tobacco for cigarettes. The patient's disease was severe enough to eventually require bilateral below-knee amputations. The association of smokeless tobacco with progressive limb ischemia should lead clinicians to discourage the substitution of smokeless tobacco for cigarette smoking in patients with Buerger's disease.

Rauchlose Tabakprodukte und die Folgen ihres Gebrauchs für die Gesundheit

Smokeless tobacco products include chewing tobacco, oral tobacco and snuff for inhalation. These products are consumed without burning the tobacco. Smokeless tobacco products contain tobacco specific nitrosamines and several other carcinogenic substances and additives. Epidemiologic studies from North America, Europe, Asia and Africa provide sufficient evidence that smokeless tobacco causes oral cancer and cancer of the pancreas. The evidence for an association of smokeless tobacco with cardiovascular disease and diabetes is limited. Furthermore, there is some evidence for adverse pregnancy outcomes in pregnant women who use smokeless tobacco. The health consequences of smokeless tobacco products are discussed critically against the background of the international debate about a proposed strategy of harm reduction, which involves offering smokeless tobacco as a smoking cessation aid.

Clinico-pathological features of bladder carcinoma in women in Pakistan and smokeless tobacco as a possible risk factor.

BackgroundBladder carcinoma is one of the common urological malignancies occurring worldwide in both sexes. Use of smokeless tobacco by women is common in rural areas of Pakistan. The clinico-pathological features of bladder carcinoma in women and association of smokeless tobacco as a possible risk factor for bladder carcinoma has not been well described in the literature. The objective of the study was to determine the clinico-pathological features of histologically confirmed bladder carcinoma in women and to investigate the role of smokeless tobacco use as a possible risk factor for its development.Patients and methodsOf the 204 patients (160 male and 44 female M:F ratio 3.6:1) of newly diagnosed bladder carcinoma treated at Nishtar Medical College Hospital Multan from January 1998 to December 2004, the 44 female patients were evaluated with respect to age, clinical presentation, cystoscopic findings, histopathological reports and possible etiological factors. Data were collected and prospectively updated at the time of discharge from hospital and during follow-up in urology out-patient clinic.ResultsTransitional cell carcinoma accounted for all of the bladder carcinoma in women. Median age of the patients was 55 years and 68% patients were under 60 years of age. Majority of patients (88%) presented with hematuria. Eleven (25%) patients had superficial (pTa/pT1) while 33 (75%) patients had muscle invasive (T2–T4) bladder carcinoma. Most (81%) superficial tumors were papillary while muscle invasive tumors had solid configuration at cystoscopy. Of these, 21 (47%) patients had long history of smokeless tobacco use (chewable or moist snuff).ConclusionTransitional cell carcinoma is the most common bladder malignancy in women in Pakistan. Many women with bladder carcinoma had long history of use of smokeless tobacco. Majority of patients presented with hematuria and were under 60 years of age. At the time of diagnosis 75% women had muscle invasive bladder carcinoma. In women using smokeless tobacco, the correlation between stage of bladder carcinoma and duration of smokeless tobacco use was significant (p = 0.03). Further studies are needed to clarify the role of smokeless tobacco in the development of bladder carcinoma.